Key Highlights

  • AbbVie (NYSE:ABBV) raised 2026 adjusted EPS guidance to USD 13.95 to USD 13.99, from USD 13.76 to USD 13.96 previously. The range is narrower than the previous guidance.
  • Q3 net Revenue was USD 17.404 billion, up 10.3%, with adjusted EPS of USD 3.82 after a USD 0.11 acquired R&D charge. Revenue growth was driven largely by immunology drugs.
  • Skyrizi sales were USD 5.776 billion and Rinvoq USD 2.706 billion, each up more than 22%, while Humira fell 31.2%. That mix shows how growth depends on newer products.
  • A planned 5.2% Dividend increase to USD 1.82 per quarter takes effect from February 2027, and shares rose about 3.2% in premarket. Both the dividend plan and the gain are subject to change.

What AbbVie Reported

AbbVie (NYSE:ABBV) reported Q3 results on October 30, 2026. Net revenue was USD 17.404 billion, up 10.3%, and adjusted EPS was USD 3.82 after an acquired R&D charge of USD 0.11. The company lifted its 2026 adjusted EPS guidance to USD 13.95 to USD 13.99, from USD 13.76 to USD 13.96. Note that the new range raises the low end more than the high end, narrowing the band. We verified these figures from a copy of the company release. We could not verify consensus EPS or revenue, so we do not claim a beat. Shares rose about 3.2% in premarket, a snapshot before the 9:30 a.m. ET open.

Growth Drivers and the Humira Drag

Skyrizi sales reached USD 5.776 billion and Rinvoq USD 2.706 billion, each up more than 22%. Together they produced about USD 8.5 billion, simple arithmetic on the two sales figures, which is nearly half of net revenue. Meanwhile Humira fell 31.2%, a drag common when a drug faces biosimilar competition and lower prices. The company's growth therefore depends on newer immunology drugs replacing that lost revenue. AbbVie (NYSE:ABBV) also announced FDA approvals and Phase 3 data, including lutikizumab in hidradenitis suppurativa and Epkinly, which broaden the pipeline. Pipeline news matters because the older product keeps shrinking. Investors should watch whether the combined growth rate holds as comparisons get harder.

Dividend, Risks and What to Watch

AbbVie (NYSE:ABBV) plans a 5.2% dividend increase to USD 1.82 per quarter from February 2027, which is a plan and not a guarantee. Risks include continued Humira erosion, concentration in two drugs, acquired R&D charges that reduce adjusted EPS and pricing pressure. Defensive sectors drew buyers while technology sold off, with the consumer staples ETF up 2.08% and the health care ETF up 1.23% in premarket. Investors tracking health care sector funds may compare the reaction. Next catalysts are the open, analyst estimate changes, which we did not find, and further trial updates. The share price reaction can also reverse once the regular session begins.

Where Things Stand

AbbVie (NYSE:ABBV) raised its 2026 adjusted EPS guidance to USD 13.95 to USD 13.99 because Skyrizi and Rinvoq each grew more than 22% and more than offset a 31.2% fall in Humira. Without verified consensus numbers we do not call the quarter a beat. The 3.2% premarket gain is a snapshot. The open and pipeline updates are the next catalysts. This is not Investment advice. Investors should watch the company's coming updates on trial results and regulatory timelines for further detail.